Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05105087
Other study ID # 21F.624
Secondary ID R21CA249870
Status Recruiting
Phase Early Phase 1
First received
Last updated
Start date April 28, 2022
Est. completion date June 30, 2026

Study information

Verified date March 2024
Source Thomas Jefferson University
Contact Ji-Bin Liu, MD
Phone 215-955-4862
Email ji-bin.liu@jefferson.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial compares the use of ultrasound for the detection of sentinel lymph nodes (SLNs) to the standard of care (which varies depending on cancer treatment). The ultrasound contrast agent is called Sonazoid and it consists of tiny gas-filled bubbles about the side of red blood cells. Diagnostic procedures, such as ultrasound with Sonazoid, may help identify more SLNs than standard of care in patients with cervical, vaginal, or vulvar cancer.


Description:

PRIMARY OBJECTIVES: I. To determine the concordance between lymphosonography and the standard of care in the identification sentinel lymph nodes (SLNs) in patients with cervical, vaginal or vulvar cancer. II. To determine if lymphosonography can identify more SLNs with metastatic deposits in patients with cervical, vaginal or vulvar cancer when compared to the standard of care. OUTLINE: Patients receive perflubutane microbubble (Sonazoid) injections subdermally and then undergo ultrasound over 30 minutes before standard of care cancer treatment. After completion of study intervention, patients are followed up for 30 days.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date June 30, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Be female - Be diagnosed with cervical, vaginal or vulvar cancer - Be at least 18 years of age - If of child-bearing potential, must have a negative pregnancy test - Be able to comply with study procedures - Have read and signed the Institutional Review Board (IRB)-approved informed consent form for participating in the study Exclusion Criteria: - Females who are pregnant or nursing - Patients who have received an investigational drug in the 30 days before study drug administration, or will receive one within 72 hours afterwards - Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable. For example: - Patients on life support or in a critical care unit - Patients with clinically unstable cardiac arrhythmias, such as recurrent ventricular tachycardia - Patients with recent cerebral hemorrhage - Patients who have undergone surgery within 24 hours prior to the study sonographic examination - Patients with congenital heart defects - Patient with a known allergy to Sonazoid (including an anaphylactic allergy to eggs or egg products)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Perflubutane Microbubble
Given subdermally
Procedure:
Contrast-Enhanced Ultrasound
Undergo ultrasound

Locations

Country Name City State
United States Sidney Kimmel Cancer Center at Thomas Jefferson University Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Thomas Jefferson University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of sentinel lymph nodes (SLNs) identified by lymphosonography as well as blue dye or positron emission tomography (PET)-computed tomography (CT) The number of SLN detected by contrast enhanced ultrasound will be compared to the number of SLN detected by the standard of care (i.e., by blue dye or by PET-CT) using paired t-test or paired Wilcoxon test (depending on whether the data is normal distributed or not). 30 minutes. Analysis of imaging modalities and pathology is number of sentinel lymph nodes identified therefore there not an issue with units of measurement.
Secondary Locations, depth beneath the skin surface and size (measured in three orthogonal dimensions) of each Sentinel Lymph Nodes (SLN) Will be recorded. The time frame is the duration of an ultrasound study which is 30 minutes where the sentinel lymph node will be identified and measured.
Secondary Presence or absence of metastatic deposits in the Sentinel Lymph Node (SLNs) The percentage of SLNs with metastatic deposits identified by lymphosonography and by blue dye will be pairwise compared after eliminating the SLNs identified by both methods using two-sample t-test or Wilcoxon test (again after testing for normalcy). The histopathological assessment of the surgically removed lymph nodes will serve as the reference standard. Time frame for lymphosonography is 30 minutes. Blue dye information available in pathology report in 7 days
See also
  Status Clinical Trial Phase
Completed NCT05458869 - Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
Not yet recruiting NCT04483557 - Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility Phase 2
Terminated NCT04099277 - A Study of LY3435151 in Participants With Solid Tumors Phase 1
Recruiting NCT04452526 - I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination N/A
Active, not recruiting NCT04443296 - Study of Tumor Infiltrating Lymphocytes Following CCRT in the Treatment of Patients With Cervical Carcinoma Phase 1
Recruiting NCT05180851 - Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study Early Phase 1
Withdrawn NCT03220009 - Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma Phase 2
Completed NCT02460237 - HPV Self-Test Intervention in Ohio Appalachia N/A
Terminated NCT00924066 - Ixabepilone to Treat Cervical Cancer Phase 2
Completed NCT04208724 - Support Program for Adoption of Cancer Screening Interventions at a Rural Community-Based Organization N/A
Completed NCT03307044 - Fractional CO2 Laser Therapy for Survivors of Breast Malignancies N/A
Recruiting NCT05139368 - Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer N/A
Completed NCT03180294 - Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer Phase 2
Recruiting NCT05366478 - A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors Phase 1
Completed NCT03849469 - A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors Phase 1
Terminated NCT03345784 - Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers Phase 1
Completed NCT02523365 - HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Cervical Carcinoma Phase 1/Phase 2
Completed NCT03372720 - Fractional CO2 Laser Therapy in Minimizing Genitourinary Syndrome of Menopause in Gynecological Cancer Survivors N/A
Active, not recruiting NCT03752398 - A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) Phase 1
Active, not recruiting NCT00867464 - Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls